AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2358274 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Aulhorn flicker test and VEP
Number of subjects: 405
Study 391257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (1200 mg daily for 7 days)
Number of subjects: 8
Study 391257 — intervention group
Group type: COMPARATOR
Intervention: Control (no valproic acid)
Number of subjects: 8
Study 31385203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and physical training program
Number of subjects: 93
Study 31385203 — intervention group
Group type: COMPARATOR
Intervention: Usual standard care
Number of subjects: 93
Study 31060528 — intervention group
Group type: EXPERIMENTAL
Intervention: SWEL (Social Wellbeing and Engaged Living) intervention
Number of subjects: 0
Study 31060528 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending intervention
Number of subjects: 0
Study 31060528 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Session Psycho-Education
Number of subjects: 0
Study 28074355 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual pedagogy intervention in dental check-ups and preventive practices
Number of subjects: 40
Study 28074355 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visual pedagogy intervention)
Number of subjects: 40
Study 25254902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and fentanyl 2 μg/ml
Number of subjects: 310
Study 25254902 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 μg/ml alone
Number of subjects: 310
Study 23942329 — intervention group
Group type: COMPARATOR
Intervention: CHOP (n=48)
Number of subjects: 93
Study 23942329 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (n=45)
Number of subjects: 93
Study 23942329 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (BCL2 positive ABC subtypes)
Number of subjects: 93
Study 23942329 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (LMO2 positive ABC subtypes)
Number of subjects: 93
Study 21270174 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) A (600 μmol/L)
Number of subjects: 178
Study 21270174 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) B (900 μmol/L)
Number of subjects: 178
Study 21270174 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 178
Study 18563061 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cigarette
Number of subjects: 62
Study 18563061 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized cigarette
Number of subjects: 62
Study 18563061 — intervention group
Group type: EXPERIMENTAL
Intervention: Total group
Number of subjects: 62
Study 16925010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum during lecture, lab, and studying
Number of subjects: 0
Study 16925010 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-study CD
Number of subjects: 0
Study 16925010 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture + lab
Number of subjects: 0
Study 14983962 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PSA < 4 ng/mL
Number of subjects: 21169
Study 14983962 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PSA < 1 ng/mL, age < 55 years, first 18 months
Number of subjects: 21169
Study 14983962 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PSA > 2.5 ng/mL, age < 55 years
Number of subjects: 21169
Study 14983962 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval between determinations > 42 months
Number of subjects: 21169
Study 14983962 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval between determinations 18-42 months
Number of subjects: 21169
Study 14983962 — intervention group
Group type: EXPERIMENTAL
Intervention: Every additional year of age
Number of subjects: 21169
Study 14983962 — intervention group
Group type: EXPERIMENTAL
Intervention: Every unit of basal PSA
Number of subjects: 21169
Study 10929878 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg p.o. 3 h after sucralfate (2 g)
Number of subjects: 27
Study 10929878 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg p.o. 3 h after ferrous sulphate (325 mg)
Number of subjects: 27
Study 10929878 — intervention group
Group type: COMPARATOR
Intervention: Gemifloxacin 320 mg p.o. 2 h before sucralfate
Number of subjects: 27
Study 10929878 — intervention group
Group type: COMPARATOR
Intervention: Gemifloxacin 320 mg p.o. 2 h before ferrous sulphate
Number of subjects: 27
Study 8957726 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic patients
Number of subjects: 36
Study 8957726 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 36
Study 1398631 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic formulas Ya and Yc
Number of subjects: 212
Study 3927357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 12
Study 3927357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1 mg
Number of subjects: 12
Study 3927357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30471452 — intervention group
Group type: EXPERIMENTAL
Intervention: Measuring units based on other body part
Number of subjects: 0
Study 30471452 — intervention group
Group type: COMPARATOR
Intervention: Measuring units based on non-body object
Number of subjects: 0
Study 30269898 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 30269898 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of whey protein microgels (WPM30)
Number of subjects: 17
Study 30269898 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of whey protein microgels (WPM50)
Number of subjects: 17
Study 30269898 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g micellar casein (MC50)
Number of subjects: 17
Study 29029015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol 100 mg
Number of subjects: 15
Study 29029015 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol 150 mg
Number of subjects: 15
Study 29029015 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 20 mg
Number of subjects: 15
Study 25449224 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive wrap
Number of subjects: 801
Study 25449224 — intervention group
Group type: COMPARATOR
Intervention: No wrap
Number of subjects: 801
Study 23545347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (20,000 units/kg)
Number of subjects: 36
Study 23545347 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 36
Study 21469532 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with BMI <35 and weight < 102 kg
Number of subjects: 51
Study 21469532 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with BMI >35 and weight >102 kg
Number of subjects: 51
Study 19453581 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal group (allowed to eat and drink upon request)
Number of subjects: 147
Study 19453581 — intervention group
Group type: COMPARATOR
Intervention: Fasting group (fasted for 6 hours)
Number of subjects: 147
Study 19453581 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal group
Number of subjects: 147
Study 16461133 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 SQ-U
Number of subjects: 410
Study 16461133 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 SQ-U
Number of subjects: 410
Study 16461133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 16461133 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life measures
Number of subjects: 410
Study 15265255 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/COM (abacavir 300 mg + lamivudine 150 mg/zidovudine 300 mg combination tablet)
Number of subjects: 342
Study 15265255 — intervention group
Group type: COMPARATOR
Intervention: IDV/COM (indinavir 800 mg + lamivudine 150 mg/zidovudine 300 mg combination tablet)
Number of subjects: 342
Study 11975764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily at bedtime
Number of subjects: 21
Study 11975764 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg each evening
Number of subjects: 21
Study 11975764 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 21
Study 11975764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 21
Study 11975764 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 21
Study 11975764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 21
Study 11975764 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 21
Study 9043473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice and protein‐rich supplements for 4 months
Number of subjects: 53
Study 9043473 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 53
Study 7938088 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium depletion treatment (KD1, KD2, KD3)
Number of subjects: 20
Study 7938088 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium depletion treatment (KD2, KD3)
Number of subjects: 20
Study 7938088 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium depletion treatment (KD3)
Number of subjects: 20
Study 7938088 — intervention group
Group type: COMPARATOR
Intervention: Normokalemic controls (N)
Number of subjects: 20
Study 2965159 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-amino acid human atrial natriuretic peptide (hANP-(99-126))
Number of subjects: 6
Study 2965159 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-amino acid human atrial natriuretic peptide (ANP-(101-126))
Number of subjects: 6
Study 2965159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31679408 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 200 mg dissolved in water
Number of subjects: 58
Study 31679408 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine digluconate (CHX) mouthwash
Number of subjects: 58
Study 29273262 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy weekend-less (CHARTWEL)
Number of subjects: 160
Study 29273262 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy (CF)
Number of subjects: 160
Study 26868074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Pillow
Number of subjects: 240
Study 26868074 — intervention group
Group type: COMPARATOR
Intervention: Control (without Fetal Pillow)
Number of subjects: 240
Study 24232638 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Number of subjects: 75
Study 24232638 — intervention group
Group type: COMPARATOR
Intervention: Usual-care program
Number of subjects: 75
Study 24232638 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 75
Study 23281842 — intervention group
Group type: EXPERIMENTAL
Intervention: ergocalciferol, 50.000 IU/week for 6 weeks
Number of subjects: 43
Study 23281842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ergocalciferol treatment)
Number of subjects: 43
Study 20173087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum during HIPEC
Number of subjects: 40
Study 19892915 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-induced cross-linking
Number of subjects: 0
Study 19892915 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape seed extract-induced cross-linking
Number of subjects: 0
Study 16982281 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% citric acid plus 2.5% NaOCl
Number of subjects: 80
Study 16982281 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% EDTA plus 2.5% NaOCl
Number of subjects: 80
Study 16982281 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% orthophosphoric acid plus 2.5% NaOCl
Number of subjects: 80
Study 16982281 — intervention group
Group type: COMPARATOR
Intervention: 2.5% NaOCl
Number of subjects: 80
Study 15765034 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ambulation with compression stockings
Number of subjects: 53
Study 15765034 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ambulation with Unna boot bandages
Number of subjects: 53
Study 15765034 — intervention group
Group type: COMPARATOR
Intervention: Bed rest with no compression
Number of subjects: 53
Study 11195984 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of a threatening interpretation of ambiguous information
Number of subjects: 0
Study 11195984 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of a benign interpretation of ambiguous information
Number of subjects: 0
Study 11195984 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 0
Study 11195984 — intervention group
Group type: EXPERIMENTAL
Intervention: Active processing of personally relevant meanings
Number of subjects: 0
Study 9285181 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 56
Study 9285181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9285181 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (ID genotype)
Number of subjects: 56
Study 9285181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ID genotype)
Number of subjects: 56
Study 8301065 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus propranolol
Number of subjects: 85
Study 8301065 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 85
Study 3579659 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30
Study 3579659 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 30
Study 3579659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3579659 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol vs Amitriptyline
Number of subjects: 30
Study 3579659 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Amitriptyline
Number of subjects: 30
Study 31311427 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch condition (change between fore- and rear-foot strike pattern every 30 s during downhill sections)
Number of subjects: 14
Study 31311427 — intervention group
Group type: COMPARATOR
Intervention: Control condition (without change in foot strike pattern)
Number of subjects: 14
Study 28849682 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (100,000 IU monthly)
Number of subjects: 65
Study 28849682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26335670 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardians
Number of subjects: 176
Study 26335670 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients
Number of subjects: 176
Study 26335670 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients and Guardians
Number of subjects: 176
Study 26335670 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patient age (>12 years), guardian with a college degree, obtaining consent by the attending surgeon, separate preoperative visit, use of visual aids, participation in a peer-support group
Number of subjects: 176
Study 26310180 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyamide monofilaments (bending force: 0.2, 69 and 2569mN) and a 'weighted-pin' stimulator (512mN)
Number of subjects: 23
Study 23003342 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin smart gel system (formulated with Pluronic® F‐127 and Hydroxy Ethyl Cellulose)
Number of subjects: 0
Study 15931642 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB) with polyacrilonitrile filters for 4 hr thrice-weekly
Number of subjects: 48
Study 15931642 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 48
Study 15931642 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 healthy volunteers, 12 females, 12 males, mean age 55 +/- 9 yrs)
Number of subjects: 48
Study 14695360 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition group
Number of subjects: 213
Study 14695360 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group
Number of subjects: 213
Study 14695360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutrition and physical activity group
Number of subjects: 213
Study 14695360 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 213
Study 10215729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 1489
Study 10215729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 1489
Study 10215729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1489
Study 8829785 — intervention group
Group type: EXPERIMENTAL
Intervention: Teams of case managers plus peer specialists
Number of subjects: 104
Study 8829785 — intervention group
Group type: COMPARATOR
Intervention: Teams of case managers plus nonconsumer assistants
Number of subjects: 104
Study 8829785 — intervention group
Group type: COMPARATOR
Intervention: Case managers only
Number of subjects: 104
Study 2157554 — intervention group
Group type: COMPARATOR
Intervention: CDDP (120 mg/m2 x 3 weeks)
Number of subjects: 156
Study 2157554 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP (120 mg/m2) and VP‐16 (100 mg/m2 given i.v. on days 1‐3, repeated every 3 weeks)
Number of subjects: 156
Study 2157554 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP (120 mg/m2), VP‐16 (100 mg/m2 on days 1‐3), and mitomycin C (10 mg/m2 on days 1, 21, and 42, then every 6 weeks, for a maximal dose of 100 mg)
Number of subjects: 156
Study 2157554 — intervention group
Group type: COMPARATOR
Intervention: CDDP alone
Number of subjects: 156
Study 2157554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CDDP/VP‐16)
Number of subjects: 156
Study 2157554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C addition
Number of subjects: 156
Study 374164 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllocontin Continus tablets
Number of subjects: 22
Study 374164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29565189 — intervention group
Group type: EXPERIMENTAL
Intervention: INDICORE intervention (multi-faceted training on diagnostics for PCPs, supported by patient education material and a referral process tool)
Number of subjects: 0
Study 29565189 — intervention group
Group type: COMPARATOR
Intervention: Generic communication training for all clusters (control group)
Number of subjects: 0
Study 27402283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice application with scheduled over-the-counter analgesics (n=36)
Number of subjects: 68
Study 27402283 — intervention group
Group type: COMPARATOR
Intervention: Scheduled over-the-counter analgesics alone (n=32)
Number of subjects: 68
Study 26311629 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 54
Study 26311629 — intervention group
Group type: COMPARATOR
Intervention: Conventional cataract surgery
Number of subjects: 54
Study 24399584 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anterior MI
Number of subjects: 24
Study 20802298 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy
Number of subjects: 60
Study 20802298 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment
Number of subjects: 60
Study 17651830 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with 0.45% sodium chloride and acetylcysteine (1200 mg orally, twice loading dose at 12 hours before and immediately after procedure) in patients with elevated baseline creatinine.
Number of subjects: 936
Study 17651830 — intervention group
Group type: COMPARATOR
Intervention: Hydration with 0.45% sodium chloride alone in patients with normal renal function.
Number of subjects: 936
Study 17651830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CIN in the abnormal group.
Number of subjects: 936
Study 17651830 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated baseline creatinine levels.
Number of subjects: 936
Study 15774607 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a physician in prehospital setting
Number of subjects: 1639
Study 15774607 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital fibrinolysis
Number of subjects: 1639
Study 15774607 — intervention group
Group type: EXPERIMENTAL
Intervention: Country of enrollment
Number of subjects: 1639
Study 12460293 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel lidocaine/tetracaine‐based cream peel (S‐Caine)
Number of subjects: 20
Study 12460293 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream with occlusion for 30 minutes
Number of subjects: 20
Study 10337544 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mode Doppler tissue imaging
Number of subjects: 64
Study 10337544 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 matched healthy volunteers)
Number of subjects: 64
Study 8748192 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-hormone infusion (epinephrine, glucagon, hydrocortisone)
Number of subjects: 0
Study 8748192 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 0
Study 1823392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium for 2 days followed by oral magnesium (n = 12)
Number of subjects: 25
Study 1823392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 25
Study 7282519 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (FUR) added to propranolol
Number of subjects: 40
Study 7282519 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) added to propranolol
Number of subjects: 40
Study 31796515 — intervention group
Group type: EXPERIMENTAL
Intervention: NanoCind® signature
Number of subjects: 60
Study 27976374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for PTSD (CT-PTSD)
Number of subjects: 29
Study 27976374 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 29
Study 26098004 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment (early discharge followed by home treatment in combination with inpatient treatment)
Number of subjects: 92
Study 26098004 — intervention group
Group type: COMPARATOR
Intervention: Regular length inpatient treatment (control group)
Number of subjects: 92